Financial Performance - The company reported a revenue increase of 25% year-over-year, reaching RMB 1.5 billion for the fiscal year ending December 31, 2023[10]. - The company achieved a total revenue of RMB 1,369.2 million in 2024, representing a year-on-year growth of 6.4% compared to RMB 1,287.4 million in 2023[16]. - Revenue for the year ended December 31, 2024, was RMB 1,369.2 million, an increase of 6.4% from RMB 1,287.4 million in 2023, primarily due to an increase in product sales revenue of RMB 80.5 million[67]. - Product sales revenue increased by 6.6% from RMB 1,218.5 million in 2023 to RMB 1,299.0 million in 2024, driven by a 19.1% increase in sales from Bone Yodao, which rose from RMB 708.9 million to RMB 844.0 million[68]. - The net profit attributable to the company's shareholders for 2024 was RMB 138.6 million, an increase of RMB 18.8 million from RMB 119.8 million in 2023[16]. - The company achieved a net profit of RMB 138.6 million in 2024, representing a year-on-year growth of 15.7%[20]. - Gross profit increased by 9.2% from RMB 990.7 million in 2023 to RMB 1,081.7 million in 2024, with gross margin rising from 77.0% to 79.0%[71]. - The gross margin improved to 60%, up from 55% in the previous year, reflecting better cost management and pricing strategies[10]. Research and Development - Investment in R&D increased by 15%, amounting to RMB 300 million, focusing on new drug development and innovative technologies[10]. - The company has multiple competitive products in development, with significant progress reported for JY06 and JY23[12]. - The company aims to be the first domestic producer to obtain approval for the GLP-1 class drug, semaglutide, in 2025[14]. - The company plans to submit an IND application for the innovative drug JY54 (long-acting insulin analog) in 2025[21]. - JY29-2, a treatment for diabetes, became the first domestic product to submit a production license application in April 2024, and is currently in Phase III clinical trials for obesity[19]. - The company is developing JY23-2, an injectable bone repair material, with plans to submit an IND application in 2026[62]. - The company has established a diversified product portfolio with nine marketed products and nine in development as of the report date[24]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[10]. - A strategic acquisition of a biotech firm was announced, expected to enhance the company's product pipeline and increase market competitiveness[10]. - The company launched two new products in Q4 2023, contributing to a 5% increase in market share in the domestic market[10]. - The company plans to continue expanding its orthopedic product matrix and enhance market share through innovative initiatives[14]. Corporate Governance - The company has adopted the corporate governance code as its own governance practices, ensuring adherence to standards for enhancing management and protecting shareholder interests[114]. - The board consists of nine members, including two executive directors, four non-executive directors, and three independent non-executive directors, ensuring a diverse governance structure[121]. - The company has complied with the listing rules regarding the appointment of at least three independent non-executive directors, maintaining independence in governance[123]. - The board actively supervises business performance and strategic decisions, ensuring objective decision-making in the best interests of the company[118]. - The company has established a code of conduct for directors and supervisors regarding insider trading, ensuring compliance with securities trading standards[117]. Risk Management and Compliance - The company has implemented a comprehensive risk management system to identify, assess, monitor, and mitigate risks, including strategic, operational, financial, and legal risks[158]. - The company has engaged an independent internal control consultant to evaluate its internal control system, focusing on financial reporting, enterprise-level controls, and information systems control management[159]. - The company conducts regular training for senior management and employees on anti-corruption and compliance to enhance knowledge of applicable laws and regulations[160]. - The board has established comprehensive internal controls against corruption and bribery, ensuring compliance with relevant laws during the reporting period[129]. Human Resources and Diversity - The company has achieved a gender diversity ratio of 2 female directors and 2 female senior management members, with a total of 742 female employees[164]. - As of December 31, 2024, approximately 48.15% of the company's full-time employees, including senior management, are women[163]. - The company is actively seeking female candidates with diverse skills and experiences to maintain board diversity[138]. - The board's composition reflects diversity in age, ranging from 28 to 65 years[138]. Future Outlook - The company provided a positive outlook, projecting a revenue growth of 20% for the next fiscal year, aiming for RMB 1.8 billion[10]. - The company aims to reduce operational costs by 10% through efficiency improvements and automation initiatives[10]. - The company is focusing on expanding its product offerings in metabolic diseases and oncology[24].
九源基因(02566) - 2024 - 年度财报